RT Journal Article
SR Electronic
T1 Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.03.22.436441
DO 10.1101/2021.03.22.436441
A1 Carmen Camara
A1 Daniel Lozano-Ojalvo
A1 Eduardo Lopez-Granados
A1 Estela Paz-Artal
A1 Marjorie Pion
A1 Rafael Correa-Rocha
A1 Alberto Ortiz
A1 Marcos Lopez-Hoyos
A1 Marta Erro Iribarren
A1 Jose Portoles
A1 Pilar Portoles
A1 Mayte Perez-Olmeda
A1 Jesus Oteo
A1 Cecilia Berin
A1 Ernesto Guccione
A1 Antonio Bertoletti
A1 Jordi Ochando
YR 2021
UL http://biorxiv.org/content/early/2021/03/22/2021.03.22.436441.abstract
AB The rapid development and deployment of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naïve individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naïve individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has been questioned. Here we characterized SARS-CoV-2 spike-specific humoral and cellular immunity in naïve and previously infected individuals during full BNT162b2 vaccination. Our results demonstrate that the second dose increases both the humoral and cellular immunity in naïve individuals. On the contrary, the second BNT162b2 vaccine dose results in a reduction of cellular immunity in COVID-19 recovered individuals, which suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.Competing Interest StatementAntonio Bertoletti declares the filling of a patent application relating to the use of peptide pools in whole blood for detection of SARS-CoV-2 T cells (pending). The other authors declare no competing interests.